On November 19, EVEREST MED fell 4.17% in Regular Trading, trading at HK$23.3, with turnover of HK$20.97 million.
Recent disclosed developments were broadly positive, including first-time inclusion of two products in the new National Reimbursement Drug List, continued listing for another product, and shareholder approval of a strategic cooperation framework agreement and related annual caps. However, the available public information does not provide a clear fresh negative catalyst directly explaining the latest share-price weakness.
Earlier disclosures showed VELSIPITY and eravacycline were newly added to the reimbursement list effective January 1, while TARPEYO remained listed. Separately, shareholders approved the strategic cooperation framework agreement on November 16, allowing the company to proceed with the cooperation and related transactions.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments